title: Oral pulse therapy with vitamin D3 for control of secondary hyperparathyroidism.
abstract: Twelve dialysis patients received oral pulse therapy with 1-alpha-hydroxyvitamin D3 in a dose of 0.1 microgram/kg body weight twice weekly and daily calcium carbonate (1.5-3.5 g) for a period of 8-12 months. This treatment was very effective in suppressing secondary hyperparathyroidism without causing hypercalcaemia and/or hyperphosphataemia.
authors.affiliation: Division of Paediatric Nephrology, Shaare Zedek Medical Centre, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
authors.forename: S
authors.initials: S
authors.lastname: Feinstein
authors.forename: N
authors.initials: N
authors.lastname: Algur
authors.forename: A
authors.initials: A
authors.lastname: Drukker
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D002118:Calcium / Q000097:blood; D002648:Child; D002675:Child, Preschool; D002762:Cholecalciferol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D015592:Immunoradiometric Assay; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010758:Phosphorus / Q000097:blood; D006435:Renal Dialysis
chemical_list: D010281:Parathyroid Hormone; D002762:Cholecalciferol; D010758:Phosphorus; D000469:Alkaline Phosphatase; D002118:Calcium